<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02507843</url>
  </required_header>
  <id_info>
    <org_study_id>20150511</org_study_id>
    <nct_id>NCT02507843</nct_id>
  </id_info>
  <brief_title>Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis</brief_title>
  <acronym>VIDB</acronym>
  <official_title>Vitamin D as an Adjunctive Treatment in Patients With Non-Cystic Fibrosis Bronchiectasis: a Double-blind Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates vitamin D as an adjunctive treatment in patients with non-Cystic
      Fibrosis bronchiectasis, which are combined with vitamin D deficiency. Half of participants
      will receive vitamin D supplementation, while the other half will receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To define the therapeutic effect of Vitamin D in the treatment of non-Cystic Fibrosis
      bronchiectasis by means of a prospective randomized placebo-controlled double blind study
      with a follow-up of at least one year. To explore whether correction of Vitamin D deficiency
      by the oral supplementation of Vitamin D triggers the vitamin D receptors-mediated
      cathelicidin pathway and increases local or systemic concentrations of the natural
      antimicrobial polypeptide cathelicidin with enhanced eradication of bacteria.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first acute exacerbation</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>total number of exacerbations per group</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of patients with one or more exacerbations per year</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severity of diseases</measure>
    <time_frame>one year</time_frame>
    <description>FACED（FEV1% predicted, age, chronic colonization by Pseudomonas aeruginosa， radiological extent of the disease， and dyspnea） score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>using of antibiotics</measure>
    <time_frame>one year</time_frame>
    <description>types of antibiotics used during exacerbations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>one year</time_frame>
    <description>the Quality of Life-Bronchiectasis (QOL-B) questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>Vitamin D group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cholecalciferol will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will be administered by monthly oral intake. During a prospective follow-up period of one year, the patients will get the normal care with some additional tests for the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.</description>
    <arm_group_label>Vitamin D group</arm_group_label>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered in placebo group monthly for 6 months.</description>
    <arm_group_label>Placebo group</arm_group_label>
    <other_name>Migliol Placebo Oil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of non-Cystic fibrosis bronchiectasis by High Resolution CT

          -  Age 18 years or older

          -  Vitamin D deficiency [25(OH)D&lt;20 ng/mL]

          -  Informed consent

        Exclusion Criteria:

          -  Current active allergic bronchopulmonary or tuberculosis

          -  Diagnosis of any of the following: sarcoidosis, hyperparathyroidism, nephrolithiasis,
             pulmonary silicosis, Human Immunodeficiency Virus infection, liver failure, renal
             failure or malignancy

          -  Taking benzothiadiazine derivative, cardiac glycoside, carbamazepine, phenobarbital,
             phenytoin or primidone

          -  Taking dietary supplement or topical preparation containing vitamin D up to 2 months
             before first dose

          -  Treatment with any investigational medical product or device up to 4 months before
             first dose

          -  Breastfeeding, pregnant or planning a pregnancy

          -  Baseline corrected serum calcium &gt; 2.65 mmol/L

          -  Baseline serum creatinine &gt; 125 micromol/L
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>JinFu Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital , Tongji University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>JinFu Xu</last_name>
    <phone>+86-13321922898</phone>
    <email>13321922898@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital , Tongji University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kei Fei</last_name>
      <phone>+86-021-65115006</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Chalmers JD, McHugh BJ, Docherty C, Govan JR, Hill AT. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax. 2013 Jan;68(1):39-47. doi: 10.1136/thoraxjnl-2012-202125. Epub 2012 Oct 16.</citation>
    <PMID>23076388</PMID>
  </results_reference>
  <results_reference>
    <citation>Bartley J, Garrett J, Grant CC, Camargo CA Jr. Could vitamin d have a potential anti-inflammatory and anti-infective role in bronchiectasis? Curr Infect Dis Rep. 2013 Apr;15(2):148-57. doi: 10.1007/s11908-013-0321-9.</citation>
    <PMID>23371406</PMID>
  </results_reference>
  <results_reference>
    <citation>Martínez-García MÁ, de Gracia J, Vendrell Relat M, Girón RM, Máiz Carro L, de la Rosa Carrillo D, Olveira C. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J. 2014 May;43(5):1357-67. doi: 10.1183/09031936.00026313. Epub 2013 Nov 14.</citation>
    <PMID>24232697</PMID>
  </results_reference>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 22, 2015</study_first_submitted>
  <study_first_submitted_qc>July 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2015</study_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Jin-Fu Xu</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

